Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to $4.6 million.

  • Theravance Biopharma's Share-based Compensation fell 779.77% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.8 million, marking a year-over-year decrease of 733.92%. This contributed to the annual value of $21.4 million for FY2024, which is 1567.93% down from last year.
  • Latest data reveals that Theravance Biopharma reported Share-based Compensation of $4.6 million as of Q3 2025, which was down 779.77% from $4.5 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Share-based Compensation registered a high of $16.9 million during Q4 2021, and its lowest value of $4.5 million during Q2 2025.
  • Over the past 5 years, Theravance Biopharma's median Share-based Compensation value was $6.3 million (recorded in 2023), while the average stood at $8.6 million.
  • Per our database at Business Quant, Theravance Biopharma's Share-based Compensation soared by 879.04% in 2021 and then crashed by 5891.95% in 2022.
  • Theravance Biopharma's Share-based Compensation (Quarter) stood at $16.9 million in 2021, then plummeted by 58.92% to $7.0 million in 2022, then decreased by 16.2% to $5.8 million in 2023, then increased by 0.03% to $5.8 million in 2024, then dropped by 21.46% to $4.6 million in 2025.
  • Its Share-based Compensation was $4.6 million in Q3 2025, compared to $4.5 million in Q2 2025 and $4.9 million in Q1 2025.